Renaissance Technologies LLC lifted its position in HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 18.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 188,539 shares of the company's stock after buying an additional 29,239 shares during the period. Renaissance Technologies LLC owned approximately 0.11% of HUTCHMED worth $2,717,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently bought and sold shares of the company. Blue Trust Inc. boosted its holdings in shares of HUTCHMED by 99.9% in the 4th quarter. Blue Trust Inc. now owns 7,068 shares of the company's stock worth $102,000 after purchasing an additional 3,532 shares during the period. Summit Trail Advisors LLC lifted its position in shares of HUTCHMED by 14.4% in the 4th quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock worth $189,000 after purchasing an additional 1,647 shares during the period. OLD Mission Capital LLC purchased a new stake in HUTCHMED during the fourth quarter worth $230,000. Crossmark Global Holdings Inc. raised its position in shares of HUTCHMED by 10.7% in the 4th quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company's stock worth $268,000 after acquiring an additional 1,799 shares in the last quarter. Finally, ABC Arbitrage SA bought a new stake in shares of HUTCHMED in the 4th quarter valued at about $500,000. Hedge funds and other institutional investors own 8.82% of the company's stock.
HUTCHMED Price Performance
NASDAQ:HCM traded down $0.31 during trading hours on Wednesday, reaching $14.85. The company had a trading volume of 33,424 shares, compared to its average volume of 105,545. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. The business's 50 day moving average price is $14.96 and its 200-day moving average price is $15.72. HUTCHMED has a 1-year low of $11.51 and a 1-year high of $21.92.
Analyst Ratings Changes
Separately, StockNews.com raised HUTCHMED from a "hold" rating to a "buy" rating in a report on Friday, March 21st.
Get Our Latest Analysis on HUTCHMED
About HUTCHMED
(
Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
See Also
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
